EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer

Alef Batista Bezerra Barros iD, Gabriel Augusto Leite iD, Arthur Gomes de Andrade iD, Maria Danielma Dos Santos Reis iD, Luiz Henrique Agra Cavalcante-Silva iD, Marvin Paulo Lins iD

Immunology · 2026-07 · 178 (3) · 377-386

DOI: 10.1111/imm.70150 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 15.05.2026. Verfasst von Alef Batista Bezerra Barros und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cell Biology, Institute of Biological and Health Sciences, Federal University of Alagoas, Maceió, Brazil. Hauptthemen laut MEDLINE: Autoimmunity, Thymus Gland, Leishmaniasis, Leishmania. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leishmania infections profoundly reshape host immunity, yet their impact on central T‐cell development remains underappreciated. The thymus, a key site for establishing a functional and self‐tolerant T‐cell repertoire, is highly sensitive to systemic inflammatory cues. Growing evidence indicates that parasitic diseases, including leishmaniasis, can perturb thymic structure and function through direct parasite presence or sustained inflammatory stress. Such disturbances may alter thymocyte maturation, leading to reduced T‐cell output and the release of cells with aberrant specificity. Beyond compromising protective immunity, these changes may create conditions favourable to immune dysregulation, including the emergence of autoimmune manifestations and a microenvironment permissive to malignant transformation. This narrative review synthesises current findings on how Leishmania interacts with immunological tissues and highlights the thymus as a potential and overlooked target whose dysfunction may bridge infection, autoimmunity and cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoimmunityThymus GlandLeishmaniasisLeishmaniaNeoplasmsHumansAnimalsT-LymphocytesHost-Parasite InteractionsImmune Tolerance

Stichwörter der Autor:innen

Leishmania infectionautoimmunitycancer susceptibilityimmune tolerancethymic dysfunction

Autor:innen und Institutionen

  • Laboratory of Cell Biology, Institute of Biological and Health Sciences, Federal University of Alagoas, Maceió, Brazil.
  • Medical School, University of Cuiabá, Mato Grosso, Brazil.
  • Biotechnology Center, Federal University of Paraíba, João Pessoa, Brazil.
  • Brazilian National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
  • Medical Sciences and Nursing Complex, Federal University of Alagoas, Arapiraca, Brazil.
  • Laboratory of Immunology, Department of Basic Sciences in Health, Medical School, Federal University of Mato Grosso, Cuiabá, Brazil.

ORCID-Profile: Alef Batista Bezerra Barros, Gabriel Augusto Leite, Arthur Gomes de Andrade, Maria Danielma Dos Santos Reis, Luiz Henrique Agra Cavalcante-Silva, Marvin Paulo Lins

Zitieren

APA

Barros, A. B. B., Leite, G. A., de Andrade, A. G., Reis, M. D. D. S., Cavalcante-Silva, L. H. A., & Lins, M. P. (2026). Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer. Immunology, 178(3), 377-386. https://doi.org/10.1111/imm.70150

Vancouver

Barros ABB, Leite GA, de Andrade AG, Reis MDDS, Cavalcante-Silva LHA, Lins MP. Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer. Immunology. 2026;178(3):377-386. doi:10.1111/imm.70150

BibTeX
@article{Barros2026,
  author = {Barros, Alef Batista Bezerra and Leite, Gabriel Augusto and de Andrade, Arthur Gomes and Reis, Maria Danielma Dos Santos and Cavalcante-Silva, Luiz Henrique Agra and Lins, Marvin Paulo},
  title = {Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer},
  journal = {Immunology},
  year = {2026},
  volume = {178},
  number = {3},
  pages = {377--386},
  doi = {10.1111/imm.70150}
}
Kostenlos starten →